Patent Application
20110237505
Not applicable.
Not applicable.
Not applicable
1. Field
The present invention relates to the use of isoflavonoid phytoalexin compounds, Glyceollins I, II, and III, found in soy plants grown under stressed conditions, as a method of treating and/or preventing conditions such as hyperlipidemia, obesity, excessive cholesterol, cardiovascular diseases, diabetes, liver disease, and combinations thereof.
2. Description of Related Art
Obesity is reaching epidemic proportions in Western populations and is commonly attributed to the high fat consumption and the sedentary lifestyles of Western populations. It is a significant public health concern, being linked with diseases such as type 2 diabetes and cardiovascular disease. Visceral (central) obesity, in particular, is associated with insulin resistance, hyperglycaemia, hyperinsulinaemia, dyslipidaemia, hypertension, and prothrombotic and proinflammatory states. The term “metabolic syndrome” encompasses these biochemical abnormalities and clinical conditions that may or may not be associated with central obesity. Obesity is a disorder of energy balance and is associated with hyperinsulinemia, insulin resistance, and abnormalities in lipid metabolism. It is one of the most important risk factors in the development of Type II diabetes, cardiovascular disease, atherosclerosis, and certain cancers.
Because of the lower frequency of these diseases in Asian countries, attention has turned toward the Asian diet, which consists mostly of soy and soy-based food products. Adipocytes play a central role in lipid homeostasis and the maintenance of energy balance in vertebrate systems. Excess fat consumption can stimulate enlargement of existing adipocytes and induce differentiation of dormant preadipocytes into mature adipocytes. Hormones, including estradiol, are regulators of this process called adipogenesis. Soy isoflavones (also called phytoalexins) mimic certain estradiol effects by binding to estrogen receptors (ER) and thus altering adipogenesis. Adipogenesis is regulated by the peroxisome proliferator-activated receptor (PPAR-PPARα, PPARβ/δ, and PPARγ) families, the primary adipogenic transcription factors. Increasing evidence has established that soy isoflavones not only act through estrogen receptors but also exert effects through other pathways such as those regulated by PPARs.
Several researchers have shown that the isoflavone genistein (an ER agonist) can bind directly to and activate both PPARα and PPARγ. In the liver, activation of PPARα leads to increased β-oxidation of fatty acids, decreased triglyceride (TG), and very low density lipoprotein (VLDL) synthesis. It is generally accepted that the majority of the effects of the soy isoflavone genistein are mediated by changes in the expression of genes involved in cholesterol metabolism. Genistein exerts antidiabetic and hypolipidimic effects through upregulation of PPAR-regulated genes. However, little is known about the effect of genistein and other phytoalexins or phytoalexin isoflavone metabolites on fatty acid synthesis or other aspects of lipid metabolism.
The liver X receptors (LXRα and LXRβ) are additional members of the nuclear receptor superfamily that were originally identified as orphan receptors. These two receptors play a key role in the regulation of cholesterol metabolism and transport as well as glucose metabolism and inflammation. The liver X receptors (LXRs) are nuclear receptors that play central roles in the transcriptional control of lipid metabolism. LXRs function as nuclear cholesterol sensors that are activated in response to elevated intracellular cholesterol levels in multiple cell types. Once activated, LXRs induce the expression of an array of genes involved in cholesterol absorption, efflux, transport, and excretion. In addition to their function in lipid metabolism, LXRs have also been found to modulate immune and inflammatory responses in macrophages. The modulation of the activity of LXR receptors may be useful in the treatment of a number of pathophysiological states including dyslipidemia, atherosclerosis, and diabetes.
Synthetic LXR agonists promote cholesterol efflux and inhibit inflammation in vivo and inhibit the development of atherosclerosis in animal models. The ability of LXRs to integrate metabolic and inflammatory signaling makes them particularly attractive targets for intervention in human metabolic disease. There is still considerable debate whether selective activation of LXRα or LXRβ has a differential effect on cholesterol homeostasis or whether they exist as functionally redundant paralogs (X,Y). Studies using LXRα/β null mice suggest that the regulation of genes in liver and peripheral tissue involved in cholesterol homeostasis is primarily under the control of LXRα, and activation of LXRβ can partially rescue LXRα null animals from gross peripheral cholesterol accumulation. However, outside of its role in cholesterol efflux, the broader biological functions of LXRβ are emerging, yet remain unclear. Unlike ABCG1 mRNA expression, which seems to be exclusively under the transcriptional control of LXRα, ABCA1 mRNA in a number of cell types is regulated through signaling mechanisms independent of both LXR isotypes and its role in cholesterol transport. Despite this, measuring ABCA1 mRNA changes is often used as a surrogate marker for in vitro and in vivo LXR activation.
The liver is an important organ in the metabolism of lipids, carbohydrates, and proteins. Therefore, it is an attractive target organ in the study of obesity. Other tissues can also be analyzed for gene expression including mammary tissue. In primate animal model gene expression of mammary tissue was performed from oral treatments of soy protein isolate (combined with estradiol) with glyceollin-enriched soy protein isolate (combined with estradiol). Little is known about the alteration of genes in animal systems through the oral application of the glyceollins.
Of potential interest among the diet-derived compounds are the isoflavones, including genistein and daidzein that are rich in soy products. The isoflavones are also known as phytoalexins. Phytoalexins constitute a chemically heterogeneous group of low molecular weight antimicrobial compounds that are synthesized de novo and accumulate in plants in response to stress. Soy contains several phytoalexins including the constitutive isoflavones daidzein and genistein that are considered as candidates for diet-derived obesity preventive compounds. Initial interest in these compounds arose from studies that correlate consumption of soy products in Asian countries with a decreased incidence of obesity. Hence, a possible use for these compounds in obesity prevention has been suggested.
Dietary factors have been increasingly implicated in the etiology of a variety of chronic diseases. Much recent interest has focused on the role of specific bioactive components, particularly from dietary plants, in prevention or treatment of these diseases. Isoflavonoids are an important class of bioactive phytochemicals widely consumed as part of soy-based foods. Soy protein is rich in the glycosylated forms of the isoflavones genistein and daidzein, which have structural similarities to endogenous estrogens and exhibit a variety of biological functions relevant to human health. Recent evidence indicates that isoflavone metabolites may also mediate certain health-related effects of soy foods. The best-studied example is equol, which is formed from daidzein by gut bacteria in a subset of human soy consumers and various non-human species. Under the influence of stressors such as trauma or infection, daidzein may also be metabolized within soybeans to a unique class of defensive compounds called glyceollins. Prior studies have shown that glyceollins exhibit distinct effects compared with genistein and daidzein, including modulation of estrogen receptor (ER) signaling. Effects of glyceollins on other biological pathways and systems have not been investigated, however. The inventors evaluated the short-term effects of glyceollin-enriched soy protein on gene expression profiles in mammary adipose tissue. The inventors identified candidate target pathways of glyceollins and evaluated comparative effects of glyceollin-enriched soy protein with a standard soy protein isolate.
Diet is a major determinant of metabolic syndrome and related comorbid conditions, and prior findings suggest that glyceollins may competitively bind estrogen receptors (ERs) and elicit selective ER-modulating properties distinct from soy isoflavonoids. The role of specific isoflavonoids and their derivatives in modulating metabolic pathways remains poorly understood.
Gene expression DNA microarrays have provided medical researchers with a powerful tool to study the mechanisms of complex diseases such as obesity. This technology permits a more comprehensive understanding of multiple genes involved in the mechanisms behind both physiologic and pathologic conditions. Microarrays facilitate the classification of disease states according to the changes in the mRNA expressed in different cells or tissues. Gene expression profiling is the major application of DNA microarrays in the research of obesity in both animals and humans. Subcutaneous fat, visceral fat, adipocyte and preadipocyte, muscle, liver, pancreas, and cancer cells under normal and disease conditions are used in addressing the profile of gene expression in obesity.
Other research has revealed that some phytoalexins, including resveratrol, delay several diseases of ageing including cancer, atherosclerosis, Type II diabetes and even neurodegeneration. Considering the beneficial health effects of the phytoalexin resveratrol, it is reasonable to propose that other plant phytoalexins have similar beneficial activities. Most current food research based on legumes has focused on plant compounds that are constitutive; however plant food items may also contain thousands of phytoalexin compounds not present in current foods. In the legume family alone there are over two hundred phytoalexins with possible underutilized preventive benefits related to obesity. These compounds have the potential to create novel phytoalexin-enriched foods that would target and enhance obesity prevention.
In addition to genistein and daidzein, the glyceollins represent another group of phytoalexins whose biosynthesis is increased in response to stress signals. The glyceollin isomers I-III (
There is a need to develop new treatments for obesity from both synthetic and natural sources. Thus, in view of the glyceollins' modulatory effects on pathways involved in lipid and carbohydrate metabolism, including PPAR and adipocytokine signaling, lipoprotein lipase, triglyceride metabolism, and LXRs in vitro, and further in view of their lack of toxic activity, the efficacy of glyceollins as a novel obesity therapy in vivo was studied.
The present invention relates to glyceollins isolated from elicited soy which have been discovered to have modulatory effects on pathways involved in lipid and carbohydrate metabolism, including PPAR and adipocytokine signaling, lipoprotein lipase, and triglyceride metabolism, and on LXRs. These glyceollins thus would be useful in the prevention and treatment of obesity,and cardiovascular diseases.
In accordance with this discovery, it is an object of the invention to provide isolated glyceollins (Glyceollin I, II, and III) from elicited soy.
It is a further object of the invention to provide a composition containing glyceollin for preventing or minimizing obesity.
It is another object of the invention to provide a method for lowering serum total cholesterol, specifically non-high-density lipoprotein cholesterol.
It is another object of the invention to provide a method for preventing or minimizing diabetes.
It is another object of the invention to provide a method for preventing or minimizing dyslipidemia.
It is another object of the invention to provide a method for preventing or minimizing atherosclerosis.
It is another object of the invention to provide a method for preventing and treating cardiac and vascular diseases linked to obesity and hyperlipidemia.
It is another object of the invention to provide a method for preventing, minimizing, or ameliorating diabetes.
Also part of this invention is a kit, comprising a glyceollin-containing composition for preventing or minimizing obesity, for lowering serum total cholesterol, specifically non-high-density lipoprotein cholesterol, or for preventing, minimizing, or ameliorating diabetes.
Also part of this invention is a kit, comprising a glyceollin-containing composition for preventing or minimizing obesity, dyslipidemia, atherosclerosis, or diabetes.
Further information on uses for glyceollins is disclosed in U.S. patent application Ser. No. 11/118,431, published as US 2006/0246162, the disclosure of which is hereby incorporated by reference.
Provided is a method of modulating the expression of genes linked to adipocytokine signaling, carbohydrate metabolism, fatty acid metabolism, arachidonic acid metabolism, PPAR signaling, insulin signaling, lipid metabolism, extracellular matrix (ECM)-receptor interaction, or combinations thereof, in an animal, comprising administering to said animal a composition comprising at least one isolated glyceollin. The at least one isolated glyceollin may be isolated from elicited soy, and may be glyceollin I, glyceollin II, glyceollin III, or combinations thereof. The at least one isolated glyceollin may be provided in an amount of from about 100 nM to about 50 μM. The at least one isolated glyceollin may be provided in an amount of from about 1 mg/kg/animal to about 100 mg/kg/animal. The genes may be upregulated, relative to an animal that has not been administered said composition comprising at least one isolated glyceollin, and may be selected from the group consisting of: ADIPOQ; DGAT2; GPD1; GYS1; LEP; LPIN1; LPL; PLIN; PPARG; and combinations thereof. The genes may be upregulated, relative to an animal that has not been administered said composition comprising at least one isolated glyceollin, and may be selected from the group consisting of: ACACB; ACAT 1; ACOX1; AGPAT 2; AHSG; AKT1; AKT2; CAP1; CD36; CEBPB; CRK; DBI; EIF2B1; EIF4EBP1; FBP1; FOS; GPD1; GPAM; HADH; HRAS1; ITGA7; LPL; MAP2K1; ORM1; PLIN; PRKAR2B; PTGDS; PTPN1; PTPN11; SORBS1; SREBF1; VEGFA; and combinations thereof. The genes may be downregulated, relative to an animal that has not been administered said composition comprising at least one isolated glyceollin, and may be selected from the group consisting of: AEBP1; ARAF; CBL; CEBPA; CEBPD; CSN2; DOK2; DOK3; EIF4E; FRS3; G6PC; GCG; GCK; GPD2; GRB10; GRB2; GSK3B; IGF2; INS1; ITGA2; ITGA8; LDLR; NCK2; NOS2; NPY; OLR 1; PHIP; PIK3CA; PIK3R2; PPP1CA; PRKCI; PTPRF; RETN; SDC1; SHC3; SLC27A4; and combinations thereof.
Provided is a method of treating hyperlipidemia, obesity, excessive cholesterol, cardiovascular disease, liver disease, diabetes, or combinations thereof, in an animal in need thereof, comprising administering a composition comprising at least one isolated glyceollin to said animal. The at least one isolated glyceollin may be isolated from elicited soy, and may be glyceollin I, glyceollin II, glyceollin III, or combinations thereof. The at least one isolated glyceollin may be provided in an amount of from about 100 nM to about 50 μM. The at least one isolated glyceollin may be provided in an amount of from about 1 mg/kg/animal to about 100 mg/kg/animal. The method may further comprise increasing the expression in said animal of genes selected from the group consisting of: ADIPOQ; DGAT2; GPD1; GYS1; LEP; LPIN1; LPL; PLIN; PPARG; and combinations thereof, relative to an animal that has not been administered said composition comprising at least one isolated glyceollin. The method may further comprise lowering total cholesterol (TC), lowering low-density lipoprotein (LDL) cholesterol and very low density lipoprotein (VLDL) cholesterol, raising triglycerides (TG), or combinations thereof in said animal, relative to an animal that has not been administered said composition comprising at least one isolated glyceollin. The method may further comprise increasing the expression in said animal of genes selected from the group consisting of: ACACB; ACAT 1; ACOX1; AGPAT 2; AHSG; AKT1; AKT2; CAP1; CD36; CEBPB; CRK; DBI; EIF2B1; EIF4EBP1; FBP1; FOS; GPD1; GPAM; HADH; HRAS1; ITGA7; LPL; MAP2K1; ORM1; PLIN; PRKAR2B; PTGDS; PTPN1; PTPN11; SORBS1; SREBF1; VEGFA; and combinations thereof, relative to an animal that has not been administered said composition comprising at least one isolated glyceollin. The method may further comprise decreasing the expression in said animal of genes selected from the group consisting of: AEBP1; ARAF; CBL; CEBPA; CEBPD; CSN2; DOK2; DOK3; EIF4E; FRS3; G6PC; GCG; GCK; GPD2; GRB10; GRB2; GSK3B; IGF2; INS1; ITGA2; ITGA8; LDLR; NCK2; NOS2; NPY; PHIP; PIK3CA; PIK3R2; PPP1CA; PTPRF; RETN; SDC1; SHC3; SLC27A4; and combinations thereof, relative to an animal that has not been administered said composition comprising at least one isolated glyceollin.
A method of stimulating glucose uptake in an animal in need thereof is provided, comprising administering a composition comprising at least one isolated glyceollin to said animal. The at least one isolated glyceollin may be isolated from elicited soy, and may be glyceollin I, glyceollin II, glyceollin III, or combinations thereof. The at least one isolated glyceollin may be provided in an amount of from about 100 nM to about 50 μM. The at least one isolated glyceollin may be provided in an amount of from about 1 mg/kg/animal to about 100 mg/kg/animal. The composition may further comprise insulin, or a further composition comprising insulin may also be administered to said animal.
For a further understanding of the nature, objects, and advantages of the present disclosure, reference should be had to the following detailed description, read in conjunction with the following drawings, wherein like reference numerals denote like elements.
Before the subject disclosure is further described, it is to be understood that the disclosure is not limited to the particular embodiments of the disclosure described below, as variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present disclosure will be established by the appended claims.
Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about”. Accordingly, unless indicated to the contrary, the numerical parameters set forth in the instant specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the instant disclosure are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical values, however, inherently contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
It should also be understood that any numerical range recited herein is intended to include all sub-ranges subsumed therein. For example, a range of 1″ to 10″ is intended to include all sub-ranges between and including the recited minimum value of 1 and the recited maximum value of 10, that is, having a minimum value equal to or greater than 1 and a maximum value of equal to or less than 10.
In this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs.
As used herein, the term “minimize” or “reduce”, or a variant thereof, includes a complete or partial inhibition of a specified biological effect (which is apparent from the context in which the term minimize is used). The term “glyceollin” may mean both a single glyceollin and plural glyceollins when the glyceollin is defined as at least one of a selected group of glyceollins.
This disclosure describes, inter alia, the increased biosynthesis of the isoflavonoid phytoalexin compounds, Glyceollins I, II and III, in soy plants grown under stressed conditions (elicited soy) and their marked effects on LXRα and/or LXRβ function, pathways involved in lipid and carbohydrate metabolism, including PPAR and adipocytokine signaling, lipoprotein lipase, and triglyceride metabolism. To fully understand the role of glyceollins' role in liver function, the well-established model of LNCaP cancer cells in an in vitro model was used to examine the effects of glyceollins on selective gene expression. In this model, using the LNCaP cancer cells, the in vitro activity of the glyceollins on LXRα or LXRβ has been established.
The glyceollin compounds used in the compositions and methods of the present invention are naturally occurring substances which may be found in plants such as soybeans that are stressed or that have been treated with elicitors. The glyceollin compounds may be isolated from the plant sources in which they naturally occur after treatment with an elicitor, or may be synthetically prepared by processes known in the art.
It is preferred to extract the glyceollins useful in the compositions and methods of the present invention from the plant materials in which they naturally occur. A preferred method of isolating the glyceollin compounds is to extract the plant materials with an alcohol, preferably methanol or ethanol, or an aqueous methanolic solution, to remove the glyceollins from the plant material. It is preferred to comminute the plant material before extracting the glyceollin compounds to maximize recovery of glyceollin compounds from the plant material. The glyceollin compounds are isolated from the extract by conventional separation procedures, such as high performance liquid chromatography, HPLC.
In a preferred embodiment, the glyceollin compounds are isolated from a soy material. Soy materials from which the glyceollin compounds can be isolated include elicitor-treated: soy seeds, soybeans, dehulled soybeans, soy cotyldeons, soy leaf tissue, soy roots, and soy hypocotyls. In one embodiment, the glyceollins are extracted from soy seeds, with a low molecular weight organic extractant, preferably an alcohol, ethyl acetate, acetone, or ether, and most preferably aqueous ethyl alcohol or methyl alcohol.
The present disclosure demonstrates that specific glyceollins, isolated from elicited soy, displayed modulatory effect on pathways involved in lipid and carbohydrate metabolism, including PPAR and adipocytokine signaling, lipoprotein lipase, and triglyceride metabolism in vivo, as well as on LXRα or LXRβ in vitro. The modulatory effects of the glyceollins (glyceollin I, glyceollin II, glyceollin II, or combinations thereof) can be observed at between about 0.5 and about 10 μM, about 0.5 and about 5.0 μM, about 0.5 and about 1.0 μM, about 1.0 and about 10 μM, about 1.0 and about 5 μM, about 5.0 and about 10 μM, and preferably about 5.0 μM. The modulatory effects of the glyceollins on LNCaP cells were similar to that observed for genistein (
Dihydrotestosterone (DHT), dimethylsulfoxide (DMSO), and genistein, 17β-estradiol were from Sigma Chemical Co. (St. Louis, Mo.). Cell culture media and reagents were purchased from Invitrogen (Carlsbad, Calif.).
Aspergillus sojae (SRRC 1125) cultures were grown at 25° C. in the dark on potato dextrose agar. After 5 days, inoculum was prepared by harvesting conidia (3.4×107/ml) in 15 ml sterile, distilled H2O. Seeds from commercial soybean variety Asgrow 5902 were surface-sterilized for 3 min in 70% ethanol followed by a quick deionized-H2O rinse and two 2 min rinses in deionized-H2O. Seeds were presoaked in sterile deionized-H2O for 4-5 hr, and then chopped for 2 min in a Cuisinart food processor. Aspergillus sojae spore suspension (300 ml) was applied to the cut surface of seeds on each tray. All trays were stored at 25° C. in the dark for three days, rinsed with water to remove spores, and oven dried at 40° C. for 24 hrs. Seeds were ground using a Waring blender before extraction.
The glyceollins I, II, and III were extracted from the 300 g ground seeds with 1 L methanol. The glyceollins were isolated using preparative scale HPLC using two Waters 25 mm 10 mm particle size mBondapak C18 radial compression column segments combined using an extension tube. HPLC was performed on a Waters 600E System Controller combined with a Waters UV-VIS 996 detector. Elution was carried out at a flow rate of 8.0 ml/min with the following solvent system: A=acetonitrile, B=water; 5% A for 10 min, then 5% A to 90% A in 60 min followed by holding at 90% A for 20 min. The injection volume was 20 mL. The fraction containing the glyceollins was concentrated under vacuum and freeze-dried. The glyceollins were confirmed by UV-VIS spectrophotometry, mass spectrometry, and NMR. The solvents acetonitrile (HPLC grade) and methanol were purchased from Aldrich Chemical Company. Water was obtained using a Millipore system and used during sample preparation procedures and HPLC analyses. A mixture of glyceollins I (68%), II (21%), and III (11%) were isolated (see
LNCaP cells were obtained from the American Type Culture Collection (Manassas, Va.) and maintained in Media A [RPMI 1640 medium with phenol red (Invitrogen, Carlsbad, Calif.), 2 mM L-glutamine (Sigma), 100 U/mL penicillin and 100 μg/mL streptomycin (BioSource International, Camarillo, Calif.) with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, Calif.)]. Cells were incubated in the presence of 5% CO2 in air at 37° C.
Gene SuperArrays with MCF-7 Cells In Vitro.
MCF-7 cells were seeded into 75 cm2 flasks in DMEM media supplemented with 5% fetal bovine serum. On the following day media was replaced with phenol-red free DMEM supplemented with 5% charcoal stripped serum for 2 days. Cells were treated with DMSO (vehicle), 1 nM 17β-estradiol, 10 μM glyceollin mixture and 100 nM tamoxifen. Total RNA was extracted. Each array profiles the expression of a panel of 96 genes. For each array, 4 μg RNA was reverse transcribed into cDNA in the presence of gene-specific oligonucleotide primers as described in the manufacturer's protocol. cDNA template was mixed with the appropriate ready-to-use PCR master mix, equal volumes were aliquoted to each well of the same plate, and then the real-time PCR cycling program was run. Quantitative RT-PCR and Estrogen Receptor Signaling Superarray, Gaithersburg, Md., USA). Relative gene expressions were calculated by using the 2−ΔΔCt method, in which Ct indicates the fractional cycle number where the fluorescent signal reaches detection threshold. The ‘delta-delta’ method (which is described by Pfaffl et al.,) uses the normalized ΔCt value of each sample, calculated using a total of five endogenous control genes (18S rRNA, HPRT1, RPL13A, GAPDH, and ACTB). Fold change values are then presented as average fold change=2−(average ΔΔCt) for genes in treated relative to control samples. Clinical variables were characterized using descriptive statistics, and the statistical significance of differences in gene expression between groups was calculated using the student's t-test.
The inventors used 30 adult female surgically menopausal cynomolgus macaques (Macaca fascicularis) with an average age of 17.8±0.5 years. All animals had been ovariectomized for 4 yr and housed since that time in stable social groups of three to four animals each. These animals were previously enrolled in a randomized Latin-square crossover study evaluating soy isoflavone effects when given with either trace or low-dose oral estradiol. In this previous study, each social group of animals received the same experimental treatments but in a different sequence. No significant carryover effects were found for any breast endpoints across the 4-wk washout periods between treatment phases. The estradiol doses used in the previous study (equivalent to 0.09 or 0.5 mg/day in women) were less than those typically prescribed to postmenopausal women for hormone therapy (˜1.0 mg/day), and the isoflavone doses (equivalent to 0, 60, 120, or 240 mg/day in women) were within the range of human dietary or supplement exposure. There is no evidence that this level of estrogen or isoflavone exposure alters the subsequent hormonal response of the adult mammary gland. For the current study, the monkeys all received a control casein/lactalbumin-based diet for 6 wk before the start of the experiment. Animals were then randomized by social group to receive one of three diets containing the following: 1) estradiol (E2, 1 mg/1,800 kcal)+casein/lactalbumin [control (Con), n=9]; 2) E2+soy protein isolate (SPI) containing 193.6 mg/1,800 kcal isoflavonoids (n=11); and 3) E2+glyceollin-enriched soy protein (GLY) containing 188.5 mg/1,800 kcal isoflavonoids and 134.1 mg/1,800 kcal glyceollins (n=10). The control diet contained a trace amount of soy protein delivering 6.7 mg/1,800 kcal isoflavonoids. All isoflavonoid doses are expressed in aglycone equivalents. Diets were isocaloric and similar in macronutrients, cholesterol, calcium, and phosphorus. The glyceollin-enriched protein was produced by enzymatic treatment of scarred soybeans (Glycine max) to induce conversion of the parent isoflavone daidzein to glyceollins. The beans were then ground, defatted, and incorporated into a fiber concentrate. The GLY supplement contained 959.5 μg of unconjugated glyceollins per gram of product (76.8% glyceollin I, 9.9% glyceollin II, and 13.6% glyceollin III), as determined by high-pressure liquid chromatography (HPLC) and ultraviolet (UV) monitoring (visible spectrophotometry). Glyceollin HPLC analyses were performed on a Waters 600E System Controller combined with a UV-VIS 996 detector. Glyceollins were extracted and homogenized in 0.5 ml 80% EtOH, heated at 50° C. for 1 h, cooled, centrifuged at 14,000 g for 10 min, and filtered. An aliquot (20 μl) of supernatant was directly analyzed by HPLC. Glyceollins were monitored at a wavelength of 285 nm, and separations were carried out using a Vydac Multiring C18 (4.6×250 mm; 5 μm) reverse-phase column. Elution was carried out at a flow rate of 1.0 ml/min using a standard solvent system. All HPLC analyses were run in triplicate. Relative isoflavonoid content was also measured per 75 units as 61.5% genistein, 34.6% daidzein, and 3.8% glyceitein for the soy protein isolate and 52.6% genistein, 43.0% daidzein, and 4.4% glyceitein for the glyceollin-enriched protein. To balance the diets, a fiber concentrate (FIBRIM 2000®) was added to the control and SPI diets. This concentrate contained a small amount of soy protein (11.4% by weight) providing 0.17 mg isoflavonoids per gram of product (as measured by HPLC). The soy protein isolate and fiber concentrate were generously provided by Solae, a division of Dupont (St. Louis, Mo.). The glyceollin-enriched protein was provided through collaborative efforts of Solae; the Southern Regional Research Center, United States Department of Agriculture; and the Tulane University School of Medicine. Estradiol tablets were obtained from Mylan Pharmaceuticals (Morganton, W. Va.). Animals were fed approximately 120 kcal/kg body weight (BW) once daily. Daily doses of estradiol, isoflavonoids, and glyceollins were scaled to 1,800 kcal of diet (the estimated daily intake for a U.S. woman) to account for differences in metabolic rates between the monkeys and human subjects. Monkeys were thus given 66.7 μg of E2/kg BW (all groups); 0.44 mg (Con), 12.91 mg (SPI), or 12.57 mg (GLY) of isoflavonoids/kg BW; and 8.94 mg glyceollins/kg BW (GLY) each day. Of note, the initial SPI and GLY diet formulations lacked adequate palatability, requiring all the animals to be placed on the control group diet (with E2) for 1 wk 14 days into the experiment. All diets were reformulated during this time with sweetened applesauce and fed henceforth for 3 weeks without compliance problems. All procedures involving these animals were conducted in compliance with state and federal laws, standards of the U.S. Department of Health and Human Services, and guidelines established by the Wake Forest University Animal Care and Use Committee (ACUC). The facilities and laboratory animal program of Wake Forest University are fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care.
At the beginning and end of the dietary treatment period, the animals were anesthetized with ketamine and buprenorphine for breast biopsy, blood collection, uterine ultrasound, vaginal cytology, and body weight measurement. For the breast biopsy, a 1.5-cm incision was made in a preselected breast quadrant, and a small (˜0.4 g) sample of mammary gland was removed. The incision was sutured, and the animals were monitored and given analgesia during recovery following ACUC-approved clinical procedures. The biopsy site was tattooed to prevent later resampling at the same site. Half of the biopsy sample was frozen; the other half was fixed at 4° C. in 4% paraformaldehyde for 24 h and then processed for histology using standard procedures.
As shown in
The two LXR responsive genes ABCG1 and ABCA1 work in tandem as a cholesterol efflux pump. These molecular effects provide potential mechanisms by which soy glyceollins may provide protection against obesity and obesity related syndrome such as hypercholesterolemia and inflammation. LXRα and LXRβ isotypes have been studied for their critical role in limiting accumulation of free cholesterol in peripheral tissue and macrophages through regulation of reverse cholesterol transporters ATP-binding cassette, subfamily A, member 1 (ABCA1) and subfamily member G1 (ABCG1; 4-5). LXRα is primarily expressed in liver, adipose, and enterocytes where LXRβ is expressed ubiquitously.
TABLE 1 shows the results of a SuperArray analysis of genes altered by estradiol, a glyceollin mixture, and tamoxifen treatment in MCF-7 cells. Numbers in bold indicate fold changes in gene expression greater than 1.5. Upon examination of the differential effects of glyceollin and tamoxifen treatment on both SDF-1 and PgR gene expression, we sought to further investigate the differences between the two compounds using a more extensive panel of genes which are commonly altered in breast cancer and estrogen signaling by performing a superarray analyses. Based on the above real time RT-PCR data we chose to treat the MCF-7 cells for four hours with DMSO (vehicle), 1 nM E2, 100 nM tamoxifen or 10 μM glyceollin. Total RNA was extracted, quantitated and a real-time PCR array was performed. The inventors identified several genes up-regulated by Glyceollin: SREBF1, SREBF2, ACOX1, PPARA, FASN, AGPAT7, AGPAT6, SCD5, CPT2, ABCG1, ACO2, ECH1, ECHDC1, ECHDC2, ECHDC3.
2.139094176
1.631274987
Homo sapiens sterol regulatory element binding
1.531557997
Homo sapiens sterol regulatory element binding
1.53581027
Homo sapiens peroxisome proliferator-activated
Homo sapiens peroxisome proliferator-activated
1.343503426
Homo sapiens acyl-Coenzyme A oxidase 1,
1.485552921
Homo sapiens carnitine palmitoyltransferase 1A
Homo sapiens uncoupling protein 2 (mitochondrial,
Homo sapiens SERPINE1 mRNA binding protein 1
Homo sapiens fatty acid synthase (FASN), mRNA
Homo sapiens FAST kinase domains 2 (FASTKD2),
Homo sapiens infant liver cDNA, clone: HMFN1864,
Homo sapiens acyl-CoA synthetase long-chain
Homo sapiens 1-acylglycerol-3-phosphate O-
Homo sapiens 1-acylglycerol-3-phosphate O-
Homo sapiens stearoyl-CoA desaturase 5 (SCD5),
Homo sapiens stearoyl-CoA desaturase 5, mRNA
Homo sapiens stearoyl-CoA desaturase 5 (SCD5),
Homo sapiens acetyl-Coenzyme A carboxylase
Homo sapiens carnitine palmitoyltransferase 1C
Homo sapiens carnitine palmitoyltransferase II
Homo sapiens carnitine palmitoyltransferase 1B
Homo sapiens acyl-CoA synthetase medium-chain
Homo sapiens acyl-CoA synthetase short-chain
Homo sapiens acyl-CoA synthetase short-chain
Homo sapiens interleukin 1 receptor antagonist
Homo sapiens interleukin 1 receptor antagonist,
Homo sapiens ATP-binding cassette, sub-family A
Homo sapiens cDNA FLJ14266 fis, clone
Homo sapiens ATP-binding cassette, sub-family A
Homo sapiens ATP-binding cassette, sub-family A
Homo sapiens ATP-binding cassette, sub-family A
Homo sapiens ATP-binding cassette, sub-family A
Homo sapiens ATP-binding cassette, sub-family A
Homo sapiens ATP-binding cassette, sub-family A
Homo sapiens ATP-binding cassette, sub-family A
Homo sapiens ATP-binding cassette, sub-family A
Homo sapiens ATP-binding cassette, sub-family A
Homo sapiens ATP-binding cassette, sub-family A
Homo sapiens ATP-binding cassette, sub-family A
Homo sapiens ATP-binding cassette, sub-family G
Homo sapiens acyl-CoA synthetase long-chain
Homo sapiens acyl-CoA synthetase short-chain
Homo sapiens acetoacetyl-CoA synthetase (AACS),
Homo sapiens acyl-CoA synthetase short-chain
Homo sapiens insulin receptor substrate 2 (IRS2),
Homo sapiens aconitase 1, soluble (ACO1), mRNA
Homo sapiens aconitase 2, mitochondrial (ACO2),
Homo sapiens 1-acylglycerol-3-phosphate O-
Homo sapiens 1-acylglycerol-3-phosphate O-
Homo sapiens enoyl Coenzyme A hydratase 1,
Homo sapiens enoyl Coenzyme A hydratase
Homo sapiens enoyl Coenzyme A hydratase
Homo sapiens enoyl Coenzyme A hydratase
Homo sapiens enoyl Coenzyme A hydratase, short
Homo sapiens insulin-degrading enzyme (IDE),
Homo sapiens insulin-like growth factor 2 receptor
Homo sapiens leptin receptor overlapping transcript
Homo sapiens uncoupling protein 2 (mitochondrial,
Homo sapiens insulin-like growth factor binding
Homo sapiens leptin receptor overlapping transcript
Homo sapiens insulin-like growth factor 1 receptor
Homo sapiens insulin-like growth factor 1 receptor
Homo sapiens insulin-like growth factor 1 receptor
Homo sapiens insulin-like growth factor 1 receptor
Homo sapiens insulin-like growth factor 1 receptor
Homo sapiens insulin-like growth factor binding
Homo sapiens 1-acylglycerol-3-phosphate O-
Homo sapiens 1-acylglycerol-3-phosphate O-
Homo sapiens 1-acylglycerol-3-phosphate O-
Homo sapiens enoyl Coenzyme A hydratase
Homo sapiens G patch domain containing 1
Homo sapiens insulin-like growth factor 2
Homo sapiens acetyl-Coenzyme A carboxylase
Homo sapiens aconitase 1, soluble (ACO1), mRNA
Homo sapiens acyl-Coenzyme A oxidase 1,
Homo sapiens acyl-Coenzyme A oxidase-like
Homo sapiens acyl-CoA synthetase bubblegum
Homo sapiens acyl-CoA synthetase bubblegum
Homo sapiens acyl-CoA synthetase long-chain
Homo sapiens acyl-CoA synthetase long-chain
Homo sapiens acyl-CoA synthetase long-chain
Homo sapiens mRNA for KIAA0837 protein, partial
Homo sapiens long chain fatty acyl CoA synthetase
Homo sapiens acyl-CoA synthetase long-chain
Homo sapiens acyl-CoA synthetase medium-chain
Homo sapiens acyl-CoA synthetase medium-chain
Homo sapiens 1-acylglycerol-3-phosphate O-
Homo sapiens 1-acylglycerol-3-phosphate O-
Homo sapiens 1-acylglycerol-3-phosphate O-
Homo sapiens 1-acylglycerol-3-phosphate O-
Homo sapiens 1-acylglycerol-3-phosphate O-
Homo sapiens Fas (TNF receptor superfamily,
Homo sapiens Fas ligand (TNF superfamily,
Homo sapiens Fas-activated serine/threonine
Homo sapiens Fas-activated serine/threonine
Homo sapiens FAST kinase domains 1 (FASTKD1),
Homo sapiens mRNA for KIAA1800 protein, partial
Homo sapiens FAST kinase domains 2 (FASTKD2),
Homo sapiens FAST kinase domains 5 (FASTKD5),
Homo sapiens 3-hydroxy-3-methylglutaryl-
Homo sapiens 3-hydroxy-3-methylglutaryl-
Homo sapiens 3-hydroxy-3-methylglutaryl-
Homo sapiens leptin receptor overlapping
Homo sapiens lipin 1 (LPIN1), mRNA [NM_145693]
Homo sapiens lipin 2 (LPIN2), mRNA [NM_014646]
Homo sapiens lipin 3 (LPIN3), mRNA [NM_022896]
Homo sapiens perilipin (PLIN), mRNA [NM_002666]
Homo sapiens sorbin and SH3 domain containing 1
Homo sapiens cDNA FLJ12406 fis, clone
Homo sapiens uncoupling protein 1 (mitochondrial,
Homo sapiens uncoupling protein 3 (mitochondrial,
Homo sapiens vascular endothelial growth factor A
Homo sapiens vascular endothelial growth factor B
Homo sapiens ATP-binding cassette, sub-family A
TABLE 2 shows the number of significant up-regulated and down-regulated genes in mammary tissue comparing glyceollin-enriched soy protein isolate to normal soy protein isolate. The HADH gene, involved in fatty acid metabolism, was up-regulated with glyceollin treatment. Several genes involved with glycerolipid metabolism were up-regulated including GPD1, GPAM, AGPAT2, and GPAM. The PTGDS gene that is involved with arachidonic acid metabolism was up-regulated. Several genes involved with the ECM-receptor interaction were down regulated including ITGA8, SDC1, syndecan 1, and ITGA2. Up-regulated genes were ITGA7 and CD36. Several genes involved with the PPAR signaling pathway were up-regulated including LPL, PLIN, SORBS1, CD36, and DBI. Several genes involved with the insulin signaling pathway were up-regulated including PRKAR2B, SORBS1, and ACACB.
TABLE 3 shows gene expression in liver tissue treated with glyceollins, TABLE 4 shows the number of significant up-regulated (>1.5), and TABLE 5 shows the number of significant down-regulated (<1.5) genes glyceollin treated mouse liver tissue with glyceollins compared to controls.
As can be appreciated from TABLES 3, 4, and 5, treatment with glyceollins caused significant changes in gene expression. A total of 13 genes were up-regulated and 13 genes were down-regulated with glyceollin treatment. In this study the lipid metabolism gene ACOX1 was significantly up-regulated. The up-regulation of this gene may be performed in the liver to prevent excess lipid accumulation. Also, up-regulation of the AHSG and LEP genes alters regulation of body fat and insulin sensitivity.
TABLE 6 displays the number of significant up-regulated (>1.5) and TABLE 7 displays the number of significant down-regulated (<1.5) genes in mouse liver tissue treated with glyceollins (E2 added) compared to controls (E2 added). A total of 19 genes were significantly up-regulated by glyceollin treatment, and a total of 31 genes were significantly down-regulated. Again, in this study the lipid metabolism gene ACOX1 was significantly up-regulated and up regulation of the AHSG gene was detected. Several other up-regulated genes involved in lipid and cholesterol function were caused by glyceollin treatment. The SORBS1 gene is important in lipid transport and SREBF1 is involved in cholesterol transport. TABLE 7 also displays several significant down-regulated genes. INS1 is important in insulin regulation.
Cholesterol is an integral component of lipid membranes in eukaryotic cells that is required for maintaining membrane fluidity and facilitating the trafficking and signaling of membrane-associated proteins. Cholesterol is also a necessary precursor for important metabolites, such as steroid hormones, bile salts and oxysterols. Several pathways coordinate cholesterol homeostasis in the body. Briefly, in the first pathway, cells acquire cholesterol, primarily through the binding of circulating cholesterol-rich low-density lipoprotein (LDL) particles to cellular lipoprotein receptors. The receptor-ligand complex is subsequently absorbed into the cell through clathrin-mediated endocytosis, and cholesterol is then used by a variety of downstream biochemical pathways. In the second pathway, cholesterol is synthesized when intra-cellular levels are low, through activation of the SCAP/SREBP signaling cascade. SREBP (sterol regulatory element binding protein) is a transcription factor that regulates expression of numerous cholesterol synthesizing genes, and SCAP (SREBP cleavage activating protein) regulates its activity. Finally, a reverse cholesterol transport pathway is activated when the cell accumulates excess cholesterol, which must then be transported to the liver for excretion into the bile. In this third pathway, circulating high-density lipoprotein (HDL) acts as the primary acceptor of cholesterol from non-liver cells.
Genistein has been shown to produce a hypolipidemic effect through the up-regulation of genes involved in fatty acid catabolism in the liver. Of particular interest were the observed changes in the expression of genes involved in fatty acid catabolism, including ACOX1.
Subjects for this study were 30 adult female surgically menopausal cynomolgus macaques (Macaca fascicularis) with an average age of 17.8±0.5 years. All animals had been ovariectomized for 4 years and housed since this time in stable social groups of 3-4 animals each. Animals were randomized by social group to receive one of three diets containing the following: (1) casein/lactalbumin (C/L, n=9); (2) soy protein isolate containing 193.6 mg/1800 kcal isoflavones (SOY, n=11); and (3) glyceollin-enriched soy protein containing 188.5 mg/1800 kcal isoflavones and 134.1 mg/1800 kcal glyceollins (GLY, n=10). All isoflavone doses are expressed in aglycone equivalents. Each diet also included a physiologic dose of micronized 17β-estradiol (E2, 1 mg/1800 kcal), as described previously (Wood et al 2006). Additional details regarding diet production, composition, and analysis are also provided in this prior report (Wood et al 2006).
Briefly, the GLY supplement contained 959.5 μg of unconjugated glyceollins per gram of product (76.8% glyceollin I, 9.9% glyceollin II, and 13.6% glyceollin III), as determined by high pressure liquid chromatography (HPLC) and UV-monitoring (visible spectrophotometry). Relative isoflavone content was also measured using HPLC (by the manufacturer) and reported in aglycone units as 61.5% genistein, 34.6% daidzein, and 3.8% glyceitin for SOY and 52.6% genistein, 43.0% daidzein, and 4.4% glyceitin for GLY. Diets were isocaloric and similar in macronutrients, cholesterol, calcium, and phosphorus. The soy protein isolate was provided by The Solae Company (St. Louis, Mo., USA), while the glyceollin-enriched protein was provided through collaborative efforts of The Solae Company; the Southern Regional Research Center, United States Department of Agriculture; and the Tulane University School of Medicine. Estradiol tablets were obtained from Mylan Pharmaceuticals (Morganton, W. Va.).
Animals were fed ˜120 kcal per kg body weight (BW) once daily. Daily doses of isoflavones, glyceollins, and E2 were scaled to 1800 kcal of diet (rather than BW) to account for differences in metabolic rates between the monkeys and human subjects (Schneider et al 2004). Monkeys were thus given 0.44 mg (C/L), 12.91 mg (SOY), or 12.57 mg (GLY) of isoflavones/kg BW; 8.94 mg glyceollins/kg BW (GLY); and 66.7 μg of E2/kg BW (all groups) each day. All procedures involving animals were conducted in compliance with State and Federal laws, standards of the U.S. Department of Health and Human Services, and guidelines established by the Wake Forest University Instituational Animal Care and Use Committee. The facilities and laboratory animal program of Wake Forest University are fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care.
For microarray analyses, total RNA was extracted from frozen mammary fat biopsies using Tri Reagent (Molecular Research Center, Cincinnati, Ohio), purified using RNeasy Mini kit (QIAGEN, Valencia, Calif.), and quantitated using a NanoDrop ND-1000 UV-vis spectrophotometer (NanoDrop, Wilmington, Del.). Biopsy collection has been described previously (Wood et al 2006). RNA intactness and quality were confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Wilmington, Del.). The 3 highest quality samples from each group (n=12 total) were used for microarray analysis. RNA was hybridized to GeneChip Rhesus Macaque Genome Arrays (Affymetrix, Santa Clara, Calif.), washed, and scanned at Cogenics®, a Division of Clinical Data (Morrisville, N.C.). Intensity data were extracted from scanned images using GeneChip Operating Software (Affymetrix). Expression of ten gene targets related to lipid and glucose metabolism pathways (identified on microarray analysis) were determined using quantitative real-time polymerase chain reaction (qRT-PCR). Macaque-specific qRT-PCR primer-probe sets were generated for the internal control genes GAPDH and BACT, while rhesus macaque or human ABI Taqman primer-probe sets were used for target assays (see TABLE 11, showing primer/probe sets for target genes evaluated by qRT-PCR). Total RNA was extracted, quantitated, and reverse-transcribed as above from all mammary samples (n=30). Real-time PCR reactions were performed on an Applied Biosystems ABI PRISM® 7500 Fast Sequence Detection System using Taqman reagents and standard thermocycling protocol. Relative expression was determined using the ΔΔCt method calculated by ABI Relative Quantification 7500 Software v2.0.1. Stock mammary tissue was run in duplicate on each plate as an external calibrator.
For TABLE 7, Hs=Homo sapiens; Mf=Macaca fascicularis (cynomolgus macaque); Mm=Macaca mulatta (rhesus macaque).
Blood was collected at baseline and post-treatment for measurement of serum markers. Serum concentrations of total glyceollins (I-III) and soy isoflavonoids were determined by liquid chromatographic-photodiode array mass spectrometric analysis. Serum concentrations of E2, vascular and bone turnover markers (monocyte chemoattractant protein (MCP)-1, endothelin (ET)-1, and CrossLaps collagen degradation products (XLAPs)), and metabolic markers (insulin, glucagon-like peptide (GLP)-1), adiponectin, and leptin) were measured using commercially available kits and protocols for radioimmunoassay (E2, DSL-4800 ultra-sensitive from Diagnostic Systems Laboratories, Webster, Tex.) or enzyme-linked immunosorbent assays (MCP-1 and ET-1 from R&D Systems, Minneapolis, Minn.; XLAPs from Osteometer Biotech A/S, Herlev, Denmark; GLP-1 (Total), leptin, and insulin from ALPCO Diagnostics, Salem, N.H.; and adiponectin from Mercodia, Winston-Salem, N.C.). Total cholesterol (TC), high-density lipoprotein cholesterol (HDL), and triglyceride (TG) concentrations were measured using enzymatic methods on a COBAS FARA II analyzer (Roche Diagnostics, Montclair, N.J.) with standard protocols and reagents. Serum assays were run in a fully standardized clinical chemistry laboratory at Wake Forest University School of Medicine. HDL concentrations were measured using the heparin-manganese precipitation procedure. Low-density lipoprotein cholesterol (LDL) plus very low-density lipoprotein cholesterol (VLDL) was calculated as the difference between TPC and HDL. Samples from baseline and post-treatment timepoints were run at the same time for all serum measures.
Microarray data were analyzed using the GeneSifter® software program (Geospiza, Seattle, Wash.). Intensity data were RMA-normalized, converted to a log2 scale, screened for heterogeneity among samples and groups, and evaluated using supervised analysis of variance (ANOVA) and pairwise comparisons between treatments. Principal components analysis (PCA), pattern navigation, cluster analysis, heatmapping, and KEGG pathway analyses were performed on filtered data subsets, as described in results. Differences in gene numbers altered by each treatment were compared using a Chi-Square Test. Euclidean distances (representing the numeric difference between treatment vectors) were calculated as part of hierarchical clustering dendrograms using average linkage. Pathways were evaluated via KEGG analyses; a z-score>2.0 was considered a significant overrepresentation of genes in a particular pathway. Representation of differentially expressed genes within specific canonical and functional categories was evaluated using Ingenuity Pathway Analysis (IPA) software v8.0 (Ingenuity Systems, Redwood City, Calif.). Significance of gene numbers within a given category was determined in IPA using a Fisher's Exact Test with Benjamini and Hochberg correction and expressed as −log10 (P value) for each treatment group. Other data were analyzed using the SAS statistical package (version 9.1, SAS Institute; Cary, N.C.). A general linear model was used to determine mean values and calculate group differences. All data were evaluated for normal distribution and homogeneity of variances among groups. Gene expression and serum marker data were log-transformed to improve distribution, and data were then retransformed to original scale and reported as fold-change of control with 90% confidence interval. One animal in the SOY group was excluded from gene expression analyses based on poor RNA quality. Final group sizes were thus n=9 for C/L and n=10 for SOY and n=10 for GLY for qRT-PCR data. Post-treatment serum lipid and marker data were covaried by baseline values. All pairwise P-values were adjusted for the number of pairwise tests using a Bonferroni correction. A two-tailed significance level of 0.05 was chosen for all comparisons.
Body weight, serum E2, and serum isoflavonoids were measured as indicators of diet intake. Treatment groups did not differ significantly in mean BW at baseline or post-treatment, in BW change, or in serum E2 concentrations (ANOVA P>0.05 for all). Mean serum glyceollin concentrations were 134.2±34.6 nmol/L in the GLY group and negligible in the SOY group at 4 hours post-feeding (P<0.001 compared to GLY), while total serum isoflavonoid concentrations were significantly higher in the SOY and GLY groups compared to C/L group at 4 hours (P<0.001 for both) and 24 hours (P<0.05 for both) post-feeding. The SOY and GLY groups did not differ in total serum isoflavonoids at either 4 hours (P=0.59) or 24 hours (P=0.73) post-feeding; individual isoflavonoids were also comparable between the two diets. Total serum isoflavonoids for the SOY and GLY diets at 4 hours post-feeding were comparable to those reported in human soy intervention studies.
Global expression profiles showed greater numbers of genes altered by GLY compared to SOY. For example, among 139 total (named) genes with FC>1.5 and ANOVA P<0.05, a greater number were altered in the GLY group (n=111) compared to the SOY group (n=44) (P<0.001 by Chi-square test) with only 14% overlap of GLY genes with SOY genes (
Pathway analyses were used to sort altered genes by canonical and functional categories. The most overrepresented canonical pathways in IPA for altered genes in the GLY group all related to lipid, carbohydrate, and/or energy metabolism. These pathways included glycerophospholipid and glycerolipid metabolism, cytochrome p450 metabolism, and AMPK signaling (P<0.01 for all) (see TABLE 8, which shows genes significantly altered by GLY and standard soy protein diets (related to lipid, glucose, and energy metabolism) by KEGG pathway analysis; pathways were identified by KEGG analysis from gene probes with FC>1.5, P<0.05, and >2 genes altered in the pathway; only pathways with significant z-score (>2) are shown.); notable pathways include glycerolipid metabolism, peroxisome proliferator-activating receptor (PPAR) signaling, and cytochrome p450 metabolism. Overrepresentation of pathways with significant z-score or related pathways was not seen for the SOY group. The most overrepresented functional pathways in IPA for GLY genes were lipid metabolism, small molecule biochemistry, and carbohydrate metabolism (P<0.05 for all). The most significant subcategory within lipid metabolism was triacylglycerol biosynthesis (-log10 (P value)=6.9). Similar patterns were seen with KEGG pathway analysis, which revealed significant overrepresentation of altered genes (z-score>2) for the GLY group related to lipid, glucose, and energy metabolism (TABLE 8). Notable pathways here included glycerolipid metabolism, peroxisome proliferator-activating receptor (PPAR) signaling, and cytochrome p450 metabolism.
To further examine these findings, ten gene targets related to lipid and/or carbohydrate metabolism, PPAR and AMPK signaling, and/or adipocytokine activity were evaluated by qRT-PCR. Nine out of the 16 targets evaluated were upregulated in the GLY group compared to C/L (P<0.05 for all) while none of the 16 differed between SOY and C/L groups (see TABLE 9, showing dietary protein effects on relative expression of select genes related to lipid and glucose metabolism, PPAR signaling, and adipocytokine activity within mammary adipose tissue, as determined by qRT-PCR). Targets increased in the GLY group included genes for adipocytokine signaling (adiponectin and leptin), carbohydrate metabolism (glycerol-3-phosphate dehydrogenase and glycogen synthase), PPAR signaling (PPARγ and lipin1), and lipid metabolism (lipoprotein lipase and perilipin). It is worth noting that considerable crosstalk occurs among these categories and that particular molecules may thus function in multiple pathways.
#P < 0.05 vs SOY.
Serum lipid measures did not differ significantly among groups at baseline (ANOVA P>0.05 for all). Following treatment, the GLY group had lower TC and LDL+VLDL compared to C/L and SOY groups (P<0.01 for all) and greater TG compared to C/L (P=0.008) (see TABLE 10, showing treatment effects on serum lipids, vascular, bone turnover, and metabolic markers). The SOY group also had greater TG compared to the C/L group (P=0.02). No significant group differences were seen for HDL or TC to HDL ratio. No group differences were observed for serum MCP-1, ET-1, XLAPS, or metabolic markers at baseline or post-treatment (ANOVA P>0.05 for all).
TABLE 10 demonstrates that serum lipid measures did not differ significantly among groups at baseline (ANOVA P>0.05 for all). Following treatment, the glyceollin group had lower total cholesterol and low density lipoprotein+very low density lipoprotein compared to casein/lactalbumin and standard soy protein groups (P<0.01 for all) and greater triglyceride compared to casein/lactalbumin (P=0.008). The values of TABLE 10 represent mean (90% confidence interval) at post-treatment covaried by baseline measures. P values were corrected for multiple pairwise comparisons. For conversion of lipid values to SI units (mmol/l), divide by 38.67 for TC, LDL+VLDL, and HDL, and by 88.57 for TG. Symbols indicate significant differences with casein/lactalbumin group (*P<0.05, **P<0.01) or with standard soy protein group (##P<0.01).
Glyceollins are a novel class of phytoalexin compounds produced as defense molecules in response to stress by certain types of leguminous plants, most notably soy. In this study we evaluated transcriptional profiles in mammary adipose tissue resulting from glyceollin-enriched soy protein in comparison with a standard soy protein isolate. We identified a distinct gene expression profile for GLY that showed minimal overlap with that of SOY. The effects of GLY related primarily to pathways involved in lipid and carbohydrate metabolism, including PPAR and adipocytokine signaling, lipoprotein lipase, and triglyceride metabolism. The GLY diet also resulted in lower serum total cholesterol, specifically non-high-density lipoprotein cholesterol, compared to the C/L diet. These preliminary findings suggest that glyceollin-enriched soy protein has divergent effects from standard soy related to adipocyte activity and nutrient metabolism.
Diet is a major determinant of metabolic syndrome and related comorbid conditions, and dietary interventions with beneficial metabolic effects may have an important role in breast cancer prevention. Prior findings suggest that glyceollins may competitively bind estrogen receptors (ERs) and elicit selective ER-modulating properties distinct from soy isoflavonoids. The role of specific isoflavonoids and their derivatives in modulating metabolic pathways remains poorly understood. Notable genes upregulated by the GLY diet included PPARγ, adiponectin, lipin 1, and lipoprotein lipase.
Prior results have shown that glyceollins may function as natural selective ER modulators. Results of this pilot study suggest that glyceollin-enriched soy protein may also have biologically relevant effects on pathways related to lipid, carbohydrate, and energy metabolism. The present inventors' findings demonstrate that soybean treatment prior to processing may alter the profile of bioactive constituents in soy protein, leading to distinct physiologic and metabolic effects from standard soy protein isolates. This idea may also have important implications for the identification of bioactive components in other plant-based foods.
Krebs-Ringers-Hepes (KRH) buffer was prepared with 200 mL H2O, 300 μL of 1 M CaCl2, 300 μL of 1.2 M MgSO4, 300 μL of 1 M KH2PO4, 3 mL of 0.14 M KCl, 6 mL of 1 M HEPES in 1.2 M NaHCO3, and 15 mL of 2.6 M NaCl. The pH was adjusted to 7.4 H2O was added to bring the final volume to 300 mL. The resulting solution was filter sterilized with a 0.22 μm filter.
D-glucose (MW=180.16) stock solution (100 mM) was prepared by dissolving 180.16 mg D-glucose in 10 mL H2O.
Tracer working solution was prepared fresh for each plate by adding 3 μl of tracer stock solution (1 μCi/μl) to 297 μL of 100 mM D-glucose to yield 0.1 μCi [3H]2-deoxyglucose in 99 mM glucose. 10 μL was added to each well with a final volume in each well of 1000 μL=0.1 μCi at 0.99 mM D-glucose.
Insulin (MW=5808) stock solution (100 μM) was prepared by dissolving 2.90 mg insulin into 5 mL of 0.01 N HCl. To make working solutions: the stock solution was diluted 1:10 by adding 100 μL stock to 900 μL KRH buffer, giving solution A (10 μM); solution A was diluted by adding 400 μL of solution A to 932 μL KRH buffer, giving solution B (3 μM); solution A was diluted by adding 100 μL of solution A to 900 μL KRH buffer, giving solution C (1 μM); solution B was diluted by adding 100 μL of solution B to 900 μL KRH buffer, giving solution D (300 nM); solution C was diluted by adding 100 μL of solution C to 900 μL KRH buffer, giving solution E (100 nM); solution D was diluted by adding 100 μL of solution D to 900 μL KRH buffer, giving solution F (30 nM); solution E was diluted by adding 100 μL of solution E to 900 μL KRH buffer, giving solution G (10 nM); solution F was diluted by adding 100 μL of solution F to 900 μL KRH buffer, giving solution H (3 nM); solution G was diluted by adding 100 μL of solution G to 900 μL KRH buffer, giving solution I (1 nM); and solution H was diluted by adding 100 μL of solution H to 900 μL KRH buffer, giving solution J (0.3 nM). 100 μL of each concentration was added to each well with a final volume in each well of 1000 μL (1:10 dilution when added to cells).
A 10 mM stock glyceollin solution was prepared by combining 3.38 mg of mixture of glyceollin I (about 76.8%), glyceollin II (about 9.9%), and glyceollin III (about 13.6%) with 1 mL DMSO. This stock solution was kept refrigerated. To make working solutions: 80 μL of the stock solution was diluted with 3920 μL KRH buffer, giving solution A (200 μM); solution A was diluted by adding 500 μL of solution A to 335 μL KRH buffer, giving solution B (120 μM); solution A was diluted by adding 1000 μL of solution A to 1000 μL KRH buffer, giving solution C (100 μM); solution A was diluted by adding 1000 μL of solution A to 1500 μL KRH buffer, giving solution D (80 μM); solution A was diluted by adding 1000 μL of solution A to 2330 μL KRH buffer, giving solution E (60 μM); solution D was diluted by adding 1000 μL of solution D to 1000 μL KRH buffer, giving solution F (40 μM); solution F was diluted by adding 1000 μL of solution F to 1000 μL KRH buffer, giving solution G (20 μM); solution G was diluted by adding 1000 μL of solution G to 1000 μL KRH buffer, giving solution H (10 μM); and solution H was diluted by adding 1000 μL of solution H to 1000 μL KRH buffer, giving solution I (5 μM). 100 μL of each concentration was added to each well with a final volume in each well of 1000 μL (1:10 dilution when added to cells). Unless indicated otherwise (see, e.g., EXAMPLES 14 & 15), where the EXAMPLES below refer to glyceollin, a mixture of glyceollins I, II, and III, was used.
Cell culture and differentiation of murine 3T3-L1 cells is a well-accepted model for study of adipocyte differentiation, glucose uptake, and insulin action. These cells undergo a program of differentiation manifest by large lipid droplet accumulation when stimulated by the appropriate hormonal cocktail. The adipocytes express markers such as leptin and adiponectin, express Glut 4, and respond to insulin stimulation by increasing glucose uptake, similar to primary adipocytes. For these experiments, frozen preadipocytes were purchased from Zenbio (Research Triangle Park, N.C.). They were thawed at 37° C., diluted with Zenbio Preadipocyte medium, and incubated in 24-well plates at 37° C. in a humidified atmosphere containing 95% air and 5% CO2 until confluent. Signals derived from confluency were allowed by incubating for 2 more days. Preadipocyte medium was replaced with Zenbio Differentiation Medium and the cells were incubated for 3 additional days; that medium was replaced with Zenbio Adipocyte Maintenece medium for about 2 weeks when greater than 95% of the cells appeared filled with large lipid droplets.
Glucose uptake assay was performed with fully differentiated 3T3-L1 adipocytes after starving the cells of serum, insulin, and glucose in the Zenbio Adipocyte Maintenece medium by incubating at 37° C. in 1 ml Krebs Ringer Buffer for different time periods as indicated in the figures after a 1 mL wash with KRH. The next day, the cells were washed once with KRH buffer, and then KRH, insulin, and/or glyceollin solutions were added to wells 1-24 according to the challenge maps at
Pre-Incubation with KRH Alone or KRH with Glyceollin
To extend the study of EXAMPLE 11, and to test whether a glyceollin present during the 24-hour serum starvation would produce measurable effects, cells were serum-starved for 24 hours by replacing the Maintenance medium with either KRH alone, or KRH supplemented with 5 μM glyceollin. Following this serum-starvation protocol, cells were exposed to 0.3 nM insulin in KRB (a very low dose) for 30 minutes at 37° C., after which 10 μL of [3H]2-deoxyglucose in D-glucose was added. Glucose uptake was assayed as above. As shown in
Pre-Incubation with KRH Alone or KRH with Glycinol
To test whether glycinol (instead of glyceollin) present during the 24-hour serum starvation would produce measurable effects, cells were serum-starved for 24 hours by replacing the Maintenance medium with either KRH alone, or KRH supplemented with 5 μM glycinol, and the experiments otherwise carried out as set forth for EXAMPLE 12. Glycinol is a much more potent estrogen agonist than the glyceollins; Park et al. characterize glyceollin as a selective estrogen receptor modulator (SERM) and propose that glyceollin likely enhances glucose uptake via an estrogen agonist action. As shown in
Pre-Incubation with Different Glyceollins
To compare the glyceollin mixture (used above, for the prior EXAMPLES) against the individual glyceollins (I, II, and III) that make up that mixture, cells were pre-incubated for 24 hours with either the glyceollin mixure (glyceollins I, II, and III), glyceollin I, glyceollin II, or glyceollin III. As shown in
Cells were pre-incubated (serum starved) for 24 hours in KRH, then exposed to glyceollins I or III in either the presence or absence of insulin. The data of
The experiments described for EXAMPLE 11 were repeated using lower concentrations of insulin. The dose-response curve of
Glucose Uptake After 19 Hours Pre-Incubation with Glyceollin Mixture
3T3-L1 differentiated adipocytes were pre-incubated for 19 hours with either KRH or with the glyceollin mixture (glyceollins I, II, and III) at the concentrations indicated. Cells were then washed and challenged with insulin at the concentrations indicated, and the results are shown in
Glucose Uptake After 45 Minutes Pre-Incubation with Glyceollin Mixture
3T3-L1 differentiated adipocytes were exposed to either KRH for 45 minutes (see
3T3-L1 differentiated adipocytes were pre-incubated (serum-starved) for 24 hours in KRH to starve the cells of glucose and insulin, as demonstrated earlier. This provides a very sensitive assay for glucose uptake. The cells were then incubated for 45 minutes with various concentrations of the glyceollin mixture, washed, and then incubated in KRH for an additional 30 minutes. As demonstrated in
All references cited in this specification are herein incorporated by reference as though each reference was specifically and individually indicated to be incorporated by reference. The citation of any reference is for its disclosure prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such reference by virtue of prior invention.
It will be understood that each of the elements described above, or two or more together may also find a useful application in other types of methods differing from the type described above. Without further analysis, the foregoing will so fully reveal the gist of the present disclosure that others can, by applying current knowledge, readily adapt it for various applications without omitting features that, from the standpoint of prior art, fairly constitute essential characteristics of the generic or specific aspects of this disclosure set forth in the appended claims. The foregoing embodiments are presented by way of example only; the scope of the present disclosure is to be limited only by the following claims.
This application claims the benefit of U.S. Provisional Application No. 61/284,623, filed on Dec. 22, 2009, and of U.S. Provisional Application No. 61/399,224, filed on Jul. 8, 2010, each of which are hereby incorporated by reference in their entirety.
| Number | Date | Country | |
|---|---|---|---|
| 61284623 | Dec 2009 | US | |
| 61399224 | Jul 2010 | US |
